Case Study: Novartis achieves accurate vaccine R&D forecasting and optimized investment decisions with Vanguard Software Corporation

R&D innovation meets next generation forecasting abilities at a global pharma corporation

Novartis, a global pharmaceuticals company with a vaccines & diagnostics division, needed a better way to manage its long, risky R&D pipeline and make smarter vaccine investment decisions. Vanguard Software was engaged to replace fragile spreadsheet models with a scalable forecasting and optimization platform (Vanguard System) to support portfolio planning and acquisition trade‑offs.

Vanguard Software implemented an interactive, web‑based Vanguard System that simulates individual vaccine lifecycles, rolls up multi‑year company projections, and runs an Optimization Module to evaluate thousands of acquisition strategies. As a result, Novartis gained real‑time, global access to pipeline forecasts and optimized acquisition schedules, improved visibility into financial impacts of portfolio choices, and the ability to rapidly model and select strategies that meet its business objectives.

Novartis

Joachim Schwarzkopf

Senior Portfolio Manager